India Globalization Capital

India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

India Globalization Capital Receives Patent To Treat Alzheimer's With Cannabis Drug

Cassava Sciences Inc

Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment.

An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Promising Treatments

India Globalization Capital (AMEX:IGC) shares are trading higher after the company announced the issuance of a patent for the treatment of Alzheimer's disease using THC.  The company was issued a patent from the United States Patent And Trademark Office titled ‘Ultra-Low Dose THC As A Potential Therapeutic And Prophylactic Agent For Alzheimer's Disease.

Why India Globalization Capital Shares Spiked Today

India Globalization Capital, Inc. (AMEX: IGC) revealed Thursday that it has obtained a patent from the United States Patent and Trademark Office for the treatment of Alzheimer's disease. The patent (#11,065,225) is named “ Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's Disease.

India Globalization Capital Shares Skyrocket On Receiving Patent For THC Formula To Treat Alzheimer's Disease

DarkPulse, Inc.

Second Sight Medical Products

PainReform Ltd.

Best high-volume penny stocks for your watchlist right now? Check these 4 out The post Highest Volume Penny Stocks to Watch Today?

Highest Volume Penny Stocks to Watch Today? Check These 4 Out

IGC stock is moving up in a huge way today. The company is finally earning its patent for the treatment of Alzheimer's disease with cannabis.

IGC Stock: The Huge Cannabis Patent News That Has IGC Flying High

POTOMAC, Md.--(BUSINESS WIRE)--IGC Announces Issuance of Patent for the Treatment of Alzheimer's Disease Using THC

IGC Announces Issuance of Patent for the Treatment of Alzheimer's Disease Using THC

Auddia

AYRO

Which penny stocks are investors watching with AMC back in focus? The post Top Penny Stocks To Buy Now?

Top Penny Stocks To Buy Now? 10 To Watch As AMC Volatility Continues

AFC Gamma

Arena Pharmaceuticals

Canopy Growth

Corbus Pharmaceuticals Holdings

Evogene

OrganiGram Holdings Inc.

SNDL Inc.

Tilray Brands

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials

POTOMAC, Md.--(BUSINESS WIRE)-- #IGCAD1--IGC completed Final Cohort of Phase 1 clinical trial on its THC-based investigational new drug intended to alleviate symptoms of Alzheimer's disease.

IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimer's Patients

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021.

IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Completes Cohort 2 of its Phase 1 Tetrahydrocannabinol (“THC”)-Based Investigational New Drug Clinical Trial on Alzheimer's Patients.

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients

India Globalization Capital (IGC) Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients

The stock price of India Globalization Capital, Inc. (NYSEAMERICAN: IGC) increased by 15.82%. This is why it happened.

IGC Stock Price Increased 15.82%: Why It Happened

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC got patent (#10,933,082) x its cannabinoid composition & method x treating pain due to Psoriatic Arthritis, Fibromyalgia, Scleroderma & others.

IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC completed administering 1st of 3 levels of dosing of IGC-AD1 on its FDA-approved THC-based phase 1 clinical trial on patients with Alzheimer's.

Update On IGC's Phase 1 Clinical Trial on Alzheimer's Patients

The bullish conditions over cannabis stocks remain, although momentum has slowed down. International Globalization Capital works in two different sectors, Materials and Health Care (cannabis).

Cannabis Earnings: India Globalization Capital Reports Q3 Results

BETHESDA, Md.--(BUSINESS WIRE)-- #AD--IGC nominated Mr. Lynch as a Class A independent director for election at the Company's 2020 Annual Meeting of Stockholders, to be held on Jan 11 '21.

India Globalization Capital Nominates Mr. John E. Lynch to its Board of Directors

POTOMAC, MD--(BUSINESS WIRE)-- #AD--India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announced that it is enrolling participants suffering from mild to severe dementia due to Alzheimer's disease for its Phase 1 clinical trial. Our subsidiary, IGC Pharma, LLC, received approval from an Institutional Review Board (“IRB”) as previously disclosed, engaged a Principal Investigator and a study site, and began enrolling participants for a Phase 1 trial on its Investigational D

IGC Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer's Patients

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended September 30, 2020, which is the second quarter of its 2021 fiscal year, and the start of Phase 1 cannabinoid-based clinical trial for Alzheimer's Patients. Revenue in the quarter ended September 30, 2020 and September 30, 2019, were $125 thousand and $1,821 thousand, respectively. The decrease in revenue is primarily due to r

IGC Reports Financial Results for September 30, 2020 Quarter and Start of Phase 1 Cannabinoid Clinical Trial for Alzheimer's Patients

Shares of Inc. India Globalization Capital  IGC, +300.37% surged 26% in premarket trading Thursday, to extend the fourfold rocket ride in the previous session, as they head for an open at the highest level seen during regular-session hours since February 2019.

IGC's stock rallies again, after rocketing fourfold on record volume in the previous session

India Globalization Capital, Inc. (NYSE: IGC) reported Wednesday with second-quarter revenue of $1.8 million, up 125% from the same quarter in 2018, when it posted $810,000 in revenue.

India Globalization Capital More Than Doubles Revenue, Posts Q2 Net Loss of $1.32M

Holi Hemp, a subsidiary of India Globalization Capital, Inc. (NYSE: IGC), said Thursday that its application for the cultivation and harvesting of hemp was approved by Arizona’s Department of Agriculture under the terms of its industrial hemp program.

India Globalization Capital Subsidiary Secures Hemp Cultivation, Harvesting License In Arizona

DHT Holdings

Flexible Solutions

Recro Pharma

Sachem Capital

These stocks to buy are low-priced, top quality choices for growth. Here's what you need to know about each.

A-Rated Stocks to Buy Under $10

News for India Globalization Capital Stock (IGC)